Objective: Current methods do not predict the acute renal allograft injury immediately after kidney transplantation. We evaluated the diagnostic performance of urinary calprotectin for predicting immediate posttransplant allograft injury.
Introduction
The immediate function of a renal allograft within the first weeks after kidney transplantation may vary considerably. The renal allograft may immediately start urine production. In contrast, the renal allograft may be damaged. An impaired renal allograft function within the first weeks or within the first year is detrimental to the longevity of the allograft and accounts for a 40% decrease in long-term graft survival [1] [2] [3] [4] [5] . A major role of ischemia-reperfusion injury for impaired renal allograft function has been confirmed in the literature [6] .
Current methods do not predict the acute renal allograft injury immediately after kidney transplantation [7] . Recently, urinary calprotectin concentrations have been identified as a marker of acute kidney injury in the non-transplant population [8, 9] . Calprotectin is a calcium-binding complex of two proteins of the so-called S100 group. It serves as a mediator protein of the innate immune system. Calprotectin is derived predominantly from neutrophils and mononuclear cells and activates Toll-like receptor 4 thereby amplifying inflammatory activity [10] . The innate immune system plays a crucial role in the pathophysiology of ischemia-reperfusion injury in the kidney. Neutrophils and macrophages migrate into the transplant within 6 h of reperfusion and release proinflammatory cytokines and other soluble inflammatory mediators [11] . After ischemia-reperfusion injury of the tubular epithelial cells, Toll-like receptor 4 maintains and amplifies the inflammatory response [12] . In the present study we tested the hypothesis that urinary calprotectin at the first postoperative days predicts acute renal allograft injury and allograft function, i.e. estimated glomerular filtration rate (eGFR) 4 weeks, 6 months, and 12 months after transplantation.
Materials and Methods

Approval
The study protocol was in accordance with the ethical standards of the Declarations of Helsinki and Istanbul. The study was approved by the local ethics committees (Den Videnskabsetiske Komite for Region Syddanmark, Projekt-ID: and Ethik-Komitee Charité Universitä tsmedizin Berlin).
Study population
We performed a multicenter prospective-cohort study of 144 patients receiving kidney transplants. Patients who were at least 18 years old and who were scheduled to receive living donor kidney transplants or deceased donor kidney transplants were recruited. Written informed consent was obtained from all patients before entry into the study. Baseline characteristics of donors and recipients and information on organ procurement were prospectively obtained from medical records. Induction therapy, immunosuppressive therapy, concomitant medications, and transplant biopsy were all made by the clinicians at each institution according to their local protocols. Delayed graft function was defined by at least one dialysis session within 7 days of transplantation [13] . Hemodialysis within 1 week after transplantation was performed because of uremic symptoms (29% of cases), hypervolemia causing dyspnoe (50% of cases), hyperkalemia (21% of cases). The treating physicians were unaware of the calprotectin concentrations. During follow up, one recipient died during the first year posttransplant due to a cardiovascular event. Six recipients lost graft function during the first year posttransplant. eGFR was available after 12 months in 123 patients.
Enzyme-linked immunosorbent assay for urinary calprotectin and urinary kidney injury molecule-1
We collected one urine sample postoperatively. We aliquoted urine supernatants into cryovials, labeled each with a random barcode, and stored samples at 220uC. The enzyme-linked immunosorbent assay (ELISA) for urinary calprotectin was performed as previously published by our group using the PhiCal-Calprotectin assay kit (Immundiagnostik AG, Bensheim, Germany) according to the manufacturer's protocol [8, 9] . Calprotectin concentrations were measured by personnel blinded to patient information. The coefficient of variation was less than 6% Urinary kidney injury molecule-1 (KIM-1) concentrations was measured using ELISA kits according to the manufacturer's protocol (dianova, Hamburg, Germany). The coefficient of variation was less than 10%.
Assessment of allograft function
Plasma creatinine was routinely measured. The absolute change in plasma creatinine was calculated as plasma creatinine preoperatively minus the first postoperative day. Four weeks, 6 months, and 12 months after transplantation we determined estimated glomerular filtration rate (eGFR) in kidney recipients according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [14] . eGFR = 1416min(Cr/k,1) 0.411 for males, min indicates the minimum of Cr/k or 1, and max indicates the maximum of Cr/k or 1.
CKD-EPI equation is recommended in transplanted patients because it more accurately gives true glomerular filtration rate measured by plasma clearance of (99 m)Tc-diethylenetriamine pentaacetic acid [15] .
Histological findings
In 98 patients a baseline biopsy was performed at transplantation as benchmark for comparison of post-transplantation histology in case a post-transplant indication biopsy was necessary. Median number of glomeruli in the baseline biopsy was 7 (IQR, 3 to 11). The severity of lesions (arteriolar hyalinosis, arteriolosclerosis, interstitial fibrosis) was scored semiquantitatively as published [16, 17] .
Statistics
Continuous data are presented as median and interquartile range (IQR). Non-parametric Mann-Whitney test or KruskalWallis test with Dunn's Multiple Comparison Test were used as appropriate to detect differences between the groups. Frequency counts were calculated for categorical data. Differences in these categorical variables between the groups were analyzed by Chisquare test or Fisher's exact text as appropriate. Associations between variables were determined using non-parametric Spearman correlation. We performed receiver operating characteristic (ROC) curve analysis to detect the accuracy of urinary calprotectin, urinary KIM-1, and absolute change in plasma creatinine for predicting eGFR after transplantation.
We performed linear regression for associations between urinary calprotectin and eGFR four weeks after kidney transplantation while adjusting for donor age, donor gender, living-donor vs. deceased-donor status, recipient age, recipient gender, delayed graft function, recipient months on dialysis before transplantation, and use of prednisolone. For regression analyses urinary calprotectin concentrations were log-transformed to obtain normal distributed data to obtain normal distributed data as tested by Kolmogoroff-Smirnov-test. Multivariate models were constructed with backward variable selection, using P,0.05 for variable retention.
Data were analyzed using GraphPad prism software (version 5.0, GraphPad Software, San Diego, CA, USA) and SPSS for windows (version 15.0; SPSS, Chicago, IL, USA). All statistical tests were two-sided. Two-sided p-values less than 0.05 were considered to indicate statistical significance.
Results
Characteristics of cohort at baseline
Urinary calprotectin concentrations were measured in 144 patients after renal allograft transplantation. 85 transplant recipients were male (59%), and 59 were female (41%). Median age of recipients was 52 years (IQR, 45 to 59 years). The cause of chronic kidney disease was diabetic nephropathy in 14 cases (10%), hypertensive nephropathy in 19 cases (13%), chronic glomerulonephritis in 53 cases (37%), polycystic kidney disease in 22 cases (15%), and other/unknown in 36 cases (25%). The number of patients with second or more transplants was 17 (12%). Median time on dialysis before transplantation was 26 months (IQR, 4 to 71 months). 31 patients (22%) were smokers, 125 patients (87%) had hypertension, and 15 patients (10%) had a history of cardiovascular events. There was no association of calprotectin and cardiac events (Spearman r = 0.08; 95% CI, 0.08 to 0.25; P = 0.31). 68 patients (47%) received kidneys from living donors, and 76 patients (53%) from deceased donors. 101 patients (70%) received tacrolimus, 43 patients (30%) cyclosporine A, 144 patients (100%) mycophenolate acid, and 75 patients (52%) prednisolone, respectively. The clinical characteristics of patients and their allograft are shown in Table 1 .
Urinary calprotectin concentrations predict allograft function
The median urinary calprotectin concentration was 576 ng/mL (IQR, 286 to 1694 ng/mL). In the lowest calprotectin quartile eGFR was 51 mL/min/1.73 m 2 (IQR, 42 to 63 mL/min/ 1.73 m , and finally in the highest calprotectin quartile eGFR was 33 mL/min/1.73 m 2 (IQR, 21 to 58 mL/ min/1.73 m 2 ) (P = 0.004; Figure 1A ). 6 months after transplantation eGFRs were 52 mL/min/1.73 m 2 (IQR, 41 to 72 mL/ min/1.73 m 2 ) and 40 mL/min/1.73 m 2 (IQR, 26 to 58 mL/ min/1.73 m 2 ) in the lowest and highest calprotectin quartile, respectively (P,0.05; Figure 1B ). 12 months after transplantation eGFRs were 59 mL/min/1.73 m 2 (IQR, 43 to 68 mL/min/ 1.73 m 2 ) and 44 mL/min/1.73 m 2 (IQR, 27 to 62 mL/min/ 1.73 m 2 ) in the lowest and highest calprotectin quartile, respectively (P,0.05; Figure 1C ).
We observed a significant association of urinary calprotectin levels with eGFR 4 weeks after transplantation (Spearman r = 2 0.33; 95% CI, 20.47 to 20.17; P,0.001; Figure 2A ), 6 months after transplantation (Spearman r = 20.20; 95% CI, 20.36 to 2 0.03; P = 0.018), and 12 months after transplantation (Spearman r = 20.22; 95% CI, 20.39 to 20.04; P = 0.015). Figure 2B indicates that 48.6% of patients with urinary calprotectin concentrations in the highest quartile (i.e., more than 1694 ng/mL) showed an eGFR in the lowest quartile (i.e., less than 30 mL/min/1.73 m 2 ) 4 weeks after renal transplantation. On the other hand, only 8.3% of patients with urinary calprotectin concentrations in the lowest quartile (i.e., less than 286 ng/mL) showed an eGFR in the lowest quartile (relative risk, 4.3; P, 0.001; sensitivity, 0.92; 95% CI, 0.77 to 0.98; specificity, 0.48; 95% CI, 0.31 to 0.66). As the likelihood ratio equals 1.78, patients with higher urinary calprotectin concentrations more likely showed worse renal function.
The predictive effect of urinary calprotectin could be observed both in transplants from living donors and deceased donors. In transplants from living donors the relative risk was 4.9 (P = 0.039; sensitivity, 0.94; 95% CI, 0.71 to 1.00; specificity, 0.41; 95% CI, 0.18 to 0.67; likelihood ratio, 1.60). In transplants from deceased donors the relative risk was 3.5 (P = 0.030; sensitivity, 0.89; 95% CI, 0.67 to 0.99; specificity, 0.47; 95% CI, 0.24 to 0.71; likelihood ratio, 1.70).
Receiver-operating characteristic (ROC) curves showed that urinary calprotectin was able to predict the eGFR in the lowest quartile (i.e., less than 30 mL/min/1.73 m 2 ) 4 weeks after renal transplantation. Urinary calprotectin resulted in an area under curve (AUC) of 0.75 (95% CI, 0.66 to 0.84; P,0.001). Figure 3A shows ROC curves and summary data for the AUC according to eGFR 4 weeks after transplantation. Higher values for area under curve were observed with lower eGFR 4 weeks after transplantation, ranging from 0.89 (95% CI, 0.80 to 0.99; P, 0.001) with eGFR less than 15 mL/min/1.73 m 2 (n = 7) to 0.69 (95% CI, 0.60 to 0.77; P,0.001) with eGFR less than 40 mL/ min/1.73 m 2 (n = 58). When data were analyzed using the urinary calprotectin/ creatinine-ratio similar results were obtained: The median urinary calprotectin/creatinine-ratio was 1.15 ng/g (IQR 0.67 to 3.00 ng/g). In the lowest calprotectin/creatinine quartile eGFR 4 weeks after renal transplantation was 46 mL/min/1.73 m 2 (IQR, 34 to 64 mL/min/1.73 m 2 ) whereas the highest quartile showed an eGFR of 36 mL/min/1.73 m 2 (IQR, 21 to 55 mL/ min/1.73 m 2 ; P = 0.041). Receiver-operating characteristic (ROC) curves showed that urinary calprotectin/creatinine ratio was able to predict the eGFR in the lowest quartile (i.e., less than 30 mL/ min/1.73 m2) 4 weeks after renal transplantation (AUC, 0.66; 95% CI, 0.55 to 0.77; P = 0.004).
For comparison, data were obtained using urinary kidney injury molecule-1 (KIM-1). The median urinary KIM-1 was 0.56 ng/mL (IQR, 0.29 to 1.14 ng/mL). In the lowest KIM-1 quartile eGFR was 48 mL/min/1.73 m 2 ) in the lowest and highest KIM-1 quartile, respectively (P = 0.25). Urinary KIM-1 levels were associated with eGFR 4 weeks after transplantation (Spearman r = 20.23; P = 0.034). We observed that 55.0% of patients with urinary KIM-1 in the highest quartile (i.e., more than 1.14 ng/mL) showed an eGFR in the lowest quartile (i.e., less than 30 mL/min/ 1.73 m 2 ) 4 weeks after renal transplantation, and 25.0% of patients with urinary KIM-1 in the lowest quartile (i.e., less than 0.29 ng/mL) showed an eGFR in the lowest quartile (relative risk, 2.0; P = 0.11). As depicted in Figure 3B KIM-1 resulted in an AUC of 0.61 (95% CI, 0.48 to 0.75; P = 0.09), indicating that calprotectin, but not KIM-1 predicted the eGFR in the lowest quartile (i.e., less than 30 mL/min/1.73 m 2 ). We observed that urinary calprotectin was superior to current use of absolute change of plasma creatinine to predict allograft function. Urinary calprotectin resulted in an AUC of 0.76 (95% CI, 0.65 to 0.88; P,0.001) to predict eGFR less than 30 mL/ min/1.73 m 2 12 months after transplantation, whereas the absolute change of plasma creatinine resulted in an AUC of 0.57 (95% CI, 0.42 to 0.72; P = 0.38) ( Figure 3C ).
Univariate and multivariate linear regression analyses are shown in Tables 2 and 3 . Multivariate linear regression showed that higher urinary calprotectin concentrations (P,0.001), older donor age (P,0.001), and delayed graft function (P = 0.039) predicted lower eGFR four weeks after transplantation, but not donor gender, living-donor vs. deceased-donor status, recipient age, recipient gender, recipient months on dialysis before transplantation, or prednisolone. As shown in Table S1 using mixed model analyses for estimated glomerular filtration rate 4 weeks after kidney transplantation confirmed these results. We also found that that higher urinary calprotectin concentrations and older donor age predicted lower eGFR 6 months as well as 12 months after transplantation. ; P = 0.66). Furthermore, median urinary calprotectin concentrations were not significantly different between the subgroups without or with prednisolone (552 ng/mL; IQR, 262 to 1260 ng/mL; vs. 638 ng/ mL; IQR 302 to 2239 ng/mL; P = 0.29).
Patients with delayed graft function showed higher urinary calprotectin levels, however that difference was only marginally significant (819 ng/mL; IQR 346 to 2627 ng/mL; vs. 522 ng/ mL; IQR, 262 to 1308 ng/mL; P = 0.09). Multivariate logistic regression showed that living-donor vs. deceased-donor status (P = 0.003) predicted delayed graft function. In contrast urinary calprotectin (P = 0.51), donor age (P = 0.54), donor gender (P = 0.68), recipient age (P = 0.57) as well as recipient gender (P = 0.19) did not show significant effects. For delayed graft function urinary calprotectin resulted in an AUC of 0.59 (95% CI, 0.49 to 0.69; P = 0.09). For delayed graft function urinary KIM-1 resulted in an AUC of 0.52 (95% CI, 0.39 to 0.65; P = 0.74).
We also analyzed urinary calprotectin levels in a subgroup of 38 patients who were anuric before renal transplantation. We would like to emphasize that that subgroup of 38 patients were anuric before renal transplantation, but not after transplantation. 5 out of 10 previously anuric patients (50.0%) with urinary calprotectin concentrations in the highest quartile showed a creatinine clearance in the lowest quartile. On the other hand, none out of 10 previously anuric patients (0.0%) with urinary calprotectin concentrations in the lowest quartile showed a creatinine clearance in the lowest quartile (P = 0.03).
Histological findings
Histological evaluation could be performed in 98 baseline biopsies obtained at the time of transplantation. Urinary calprotectin concentrations were similar in patients receiving a graft without or with arteriolar hyalinosis (grade 0, median, 426 ng/mL (IQR, 233 to 1643 ng/mL); vs. grade .0, median, 659 ng/mL (IQR, 357 to 1260 ng/mL; P = 0.29)). Urinary calprotectin concentrations were also similar in patients receiving a graft without or with arteriolosclerosis (grade 0, median, 463 ng/ mL (IQR, 238 to 1204 ng/mL) vs. grade 1, median, 616 ng/mL (IQR, 355 to 1191 ng/mL; P = 0.52)) and receiving a graft without or with interstitial fibrosis (grade 0, median, 478 ng/mL (IQR, 241 to 1476 ng/mL) vs. grade 1, median, 724 ng/mL (IQR, 390 to 1024 ng/mL; P = 0.59)). Only 13 patients had suspected rejection during the first 4 postoperative weeks, only 1 patient showed BANFF grade 1A rejection. These data may indicate that preexisting renal lesions per se may not affect postoperative urinary calprotectin concentrations.
Discussion
In the present study we showed that postoperative urinary calprotectin predicts kidney allograft function after transplantation. We observed that use of urinary calprotectin was superior to current use of absolute change of plasma creatinine to predict allograft function after transplantation. It is noteworthy to acknowledge the biologically plausible role of calprotectin in the mechanisms of ischemic reperfusion injury after kidney transplantation. The tubular damage leads to a secondary activation of the innate immune system with immigration of granulocytes and monocytes. Moreover it leads to an amplification and activation of toll-like receptors [18] . Calprotectin is a ligand of toll-like receptors, which is constitutively expressed in both proximal and distal tubules [19] . Hall et al. [20] reported that neutrophil gelatinase-associated lipocalin predicted dialysis within one week after kidney transplantation. They reported that 34 out of 91 patients (37%) had delayed graft function, defined by at least one dialysis session within the first postoperative week [20] . However, it is well-known that the clinical decision to perform postoperative hemodialysis may be influenced by several factors beyond renal allograft function, for example fluid overload and clinical uremic status of the patient.
Looking at the results for urinary calprotectin and urinary KIM-1 it may be speculated that an increased neutrophil and macrophage response to ischemia-reperfusion injury may cause increased calprotectin levels. This may be supported by the finding that urinary calprotectin but not urinary KIM-1 was significantly associated with renal allograft function.
A study by Szeto et al. in 63 kidney transplant recipients investigated urinary mRNA of neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, interleukin-18, surfactant protein-C, and S100 calcium-binding proteins A8 and A9 according to histologic groups observed in biopsies from biopsy because of progressive worsening of allograft function. They showed that urinary mRNA of KIM-1 may provide prognostic information about renal function decline, irrespective of the kidney pathology [21] . No data are available for urinary calprotectin protein and pathology because of progressive worsening of allograft function.
The present study confirms previous reports that donor age has a large impact on allograft function. However, there is no treatment to adjust for the fact of using allografts from older subjects. It should be noted that urinary calprotectin predicted allograft function even after adjustment for donor age. Hence, measurements of urinary calprotectin may add to the diagnostic procedures.
Beside the use of urinary calprotectin for prediction of immediate renal allograft injury, its determination immediately after kidney transplantation may be helpful and a necessary step for the implementation of future strategies to improve outcome after kidney transplantation. In summary, urinary calprotectin is an early, noninvasive predictor of acute renal allograft injury after kidney transplantation. 
